The latest biotech news

News and Trends 25 Nov 2019

Novartis Enters RNA Therapeutics with Medicines Company Merger

Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to protect against cardiovascular disease in twice-yearly shots. Novartis will pay €8.8B ($9.7B) to acquire The Medicines Company, which is based in the US and focuses on developing the RNA drug inclisiran for the treatment of cardiovascular disease and renal impairment. […]

November 25, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 22 Nov 2019

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

The UK company ViiV Healthcare will begin a phase IIa trial of an antibody licensed from the National Institutes of Health in the US that could block HIV transmission for longer than current antiretroviral therapies. The antibody is currently in an ongoing phase I trial run by the National Institute of Allergy and Infectious Diseases, […]

November 22, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 21 Nov 2019

€37.4M Invested in Azeria Therapeutics’ Cancer Treatment Program

UK-based Azeria Therapeutics has raised a Series B investment round of €37.4M to fund development of novel breast cancer drugs targeting proteins called pioneer factors. The series B financing includes a €34.5M commitment from leading UK healthcare VC firm Syncona. The remainder was provided by the CRT Pioneer Fund — a specialist UK fund dedicated […]

November 21, 2019 - 3 minutesmins - By External Contributor

News and Trends 21 Nov 2019

Update: Swedish Medical Device Fails to Treat Spinal Cord Injury

Update (21/11/2019): The Swedish biotech BioArctic has terminated the clinical development of a biodegradable implant that is designed to treat spinal cord injury by encouraging the regrowth of nerve cells. The decision was made when an interim analysis in BioArctic’s phase I/II trial concluded that the treatment was ineffective. BioArctic will instead focus on developing […]

November 21, 2019 - 3 minutesmins - By Alexander Burik

crispr therapeutics vertex beta thalassemia

News and Trends 19 Nov 2019

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

CRISPR Therapeutics and its US partner Vertex Pharmaceuticals have released the first clinical results for a cell therapy made using the gene editing tool CRISPR/Cas9 in patients with genetic blood disorders. The interim results concern two patients enrolled in different phase I/II clinical trials testing the same therapy in two blood disorders: transfusion-dependent beta-thalassemia and […]

November 19, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 19 Nov 2019

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

The French company CarThera has teamed up with the US firm Kiyatec to study the effects on individual patients of an ultrasound therapy to deliver brain cancer drugs to the brain. Under the agreement, Kiyatec will test the effects of chemotherapy on cells taken from CarThera’s ongoing phase I/II trial in patients with brain cancer. […]

November 19, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 18 Nov 2019

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained protection after 12 months. The company is currently running a phase II study and plans to launch a pivotal phase III trial next year. Update […]

November 18, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 15 Nov 2019

UK Spinout Secures Over €3M to Develop Novel Anticoagulants

LUNAC Therapeutics has spun out of the University of Leeds with €3.09M of funding from the university and the VC firm Epidarex Capital for the development of anticoagulants with a lower risk for bleeding than those currently available. The new anticoagulants will target activated factor XII, a protein which company founders Helen Philippou and Richard […]

November 15, 2019 - 2 minutesmins - By External Contributor

News and Trends 14 Nov 2019

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be used to tackle solid tumors, which have so far been beyond the reach of other CAR T-cell therapies. The approved CAR T-cell therapies Kymriah and Yescarta contain genetically modified immune T-cells that can fight certain types of blood cancer. However, […]

November 14, 2019 - 2 minutesmins - By Jonathan Smith

bone marrow transplant blood cancer kiadis pharma cell therapy

News and Trends 13 Nov 2019

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood cancer, laid off half of its workforce, and switched focus to other, less advanced cell therapy programs. The abandoned phase III trial was testing Kiadis Pharma’s lead cell therapy for the treatment of graft-versus-host disease, a complication of stem cell […]

November 13, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Nov 2019

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors. The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy […]

November 12, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 11 Nov 2019

Argenx Raises Whopping €502M in Global Offering

The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M) in a global offering on the Nasdaq Stock Exchange and Euronext Brussels. Argenx’s global offering was launched last week. It consists of a private placement in Europe as well as a public offering in the […]

November 11, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Novartis Enters RNA Therapeutics with Medicines Company Merger

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

€37.4M Invested in Azeria Therapeutics’ Cancer Treatment Program

Update: Swedish Medical Device Fails to Treat Spinal Cord Injury

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

UK Spinout Secures Over €3M to Develop Novel Anticoagulants

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

Argenx Raises Whopping €502M in Global Offering

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!